Supplemental material
Journal of Biomolecular Structure and Dynamics
Volume 39, 2021 - Issue 5
Reprints and Corporate Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Academic Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
Related Research Data
Comparative QSARs for antimalarial endochins: Importance of descriptor-thinning and noise reduction prior to feature selection
Source:
Elsevier BV
Molecular docking simulations and GRID-independent molecular descriptor (GRIND) analysis to probe stereoselective interactions of CYP3A4 inhibitors
Source:
Springer Science and Business Media LLC
Generating Optimal Linear PLS Estimations (GOLPE): An Advanced Chemometric Tool for Handling 3D‐QSAR Problems
Source:
Wiley
Drug target validation: Hitting the target.
Source:
Springer Science and Business Media LLC
Development and validation of AMANDA, a new algorithm for selecting highly relevant regions in Molecular Interaction Fields.
Source:
American Chemical Society (ACS)
Design, Synthesis, and Pharmacological Characterization of N- and O-Substituted 5,6,7,8-Tetrahydro-4H-isoxazolo[4,5-d]azepin-3-ol Analogues: Novel 5-HT2A/5-HT2C Receptor Agonists with Pro-Cognitive Properties
Source:
American Chemical Society (ACS)
New Developments in Molecular Orbital Theory
Source:
American Physical Society (APS)
Mapping the Binding Site Pocket of the Serotonin 5-Hydroxytryptamine2A Receptor Ser3.36(159) PROVIDES A SECOND INTERACTION SITE FOR THE PROTONATED AMINE OF SEROTONIN BUT NOT OF LYSERGIC ACID DIETHYLAMIDE OR BUFOTENIN
Source:
American Society for Biochemistry & Molecular Biology (ASBMB)
GPCRdb in 2018: adding GPCR structure models and ligands.
Source:
Oxford University Press (OUP)
Mechanism Exploration of Arylpiperazine Derivatives Targeting the 5-HT2A Receptor by In Silico Methods.
Source:
Multidisciplinary Digital Publishing Institute
ChEMBL web services: streamlining access to drug discovery data and utilities.
Source:
Oxford University Press (OUP)
A Review of its Pharmacology and Therapeutic Potential in the Management of Major Depression
Source:
Springer Science and Business Media LLC
Scalable molecular dynamics with NAMD
Source:
Wiley
Modeling ADMET
Source:
Springer New York
Structures of the 5-HT2A receptor in complex with the antipsychotics risperidone and zotepin
Source:
Springer Science and Business Media LLC
Combined Ligand and Fragment-based Drug Design of Selective Histone Deacetylase - 6 Inhibitors.
Source:
Wiley
On a simple approach for determining applicability domain of QSAR models
Source:
Elsevier BV
What is the probability of a chance prediction of a protein structure with an rmsd of 6 å
Source:
Elsevier BV
Design of novel dopamine D2 and serotonin 5-HT2A receptors dual antagonists toward schizophrenia: An integrated study with QSAR, molecular docking, virtual screening and molecular dynamics simulations.
Source:
Informa UK Limited
Development and validation of a genetic algorithm for flexible docking.
Source:
Elsevier BV
Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders
Source:
Elsevier BV
Molecular modeling and docking studies of human 5-hydroxytryptamine 2A (5-HT2A) receptor for the identification of hotspots for ligand binding
Source:
Royal Society of Chemistry (RSC)
Aporphines with 5-HT2Areceptor activity
Source:
Wiley
What's atypical about atypical antipsychotic drugs?
Source:
Elsevier BV
Insights into Serotonin Receptor Trafficking: Cell Membrane Targeting and Internalization.
Source:
Elsevier
In vivo PET study of 5HT(2A) serotonin and D(2) dopamine dysfunction in drug-naive obsessive-compulsive disorder.
Source:
Elsevier BV
Linking provided by
